Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study

Autor: Johannes H.A.M. Kaanders, C. Le Bouder, C.M.L. van Herpen, E. Joosens, C. Van Laer, Jan B. Vermorken, H. Nguyen, Dirk Schrijvers, J. A. Castelijns, Ahmad Awada, D. Van den Weyngaert, Joseph Kerger, P.H.M. de Mulder

Publikováno v: Annals of Oncology, 15, 638-45
Annals of Oncology, 15(4), 638-45. Oxford University Press
Annals of Oncology, 15, 4, pp. 638-45
Annals of oncology
Schrijvers, D, Van Herpen, C, Kerger, J, Joosens, E, Van Laer, C, Awada, A, Van den Weyngaert, D, Nguyen, H, Le Bouder, C, Castelijns, J A, Kaanders, J & Vermorken, J B 2004, ' Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. ', Annals of Oncology, vol. 15, no. 4, pp. 638-45 . https://doi.org/10.1093/annonc/mdh145

Contains fulltext : 57819.pdf (Publisher’s version ) (Closed access) PURPOSE: To determine the safety profile and activity of the combination of docetaxel, cisplatin and 5-fluorouracil (5-FU) in chemotherapy-naive patients with squamous cell carcin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e87595f8504f013045a3294136aae2f
https://hdl.handle.net/2066/57819

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.